AbCellera Biologics Inc. (ABCL)

AbCellera Biologics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	148.57	158.32	411.54	501.14	594.12	7.55
Short-Term Investments	574.45	627.27	499.95	246.84	0	0
Cash & Cash Equivalents	723.02	785.59	911.49	747.98	594.12	7.55
Cash Growth	-11.99%	-13.81%	21.86%	25.90%	7765.96%	-27.68%
Receivables	34.42	30.59	38.59	160.58	213.24	3.28
Other Current Assets	56.51	55.81	75.41	21.25	5.97	1.81
Total Current Assets	813.95	871.99	1,025	929.8	813.33	12.64
Property, Plant & Equipment	306.08	287.7	217.26	111.62	17.92	8.48
Long-Term Investments	71.59	65.94	72.52	50.31	19.25	1.78
Goodwill and Intangibles	166.54	168.23	179.31	196.2	146.65	0
Other Long-Term Assets	104.93	94.24	46.33	30.64	8.39	0.59
Total Long-Term Assets	649.15	616.11	515.42	388.77	192.21	10.85
Total Assets	1,463	1,488	1,541	1,319	1,006	23.49
Accounts Payable	99.38	104.97	112.76	90.41	56.49	2.58
Deferred Revenue	19.14	27.15	41.13	34.95	32.48	4.57
Current Debt	0	0	0	0	0	2.08
Other Current Liabilities	-13.63	-13.11	-35.57	-4.68	14.52	-1.34
Total Current Liabilities	104.88	119.01	118.32	120.68	103.49	7.9
Long-Term Debt	68.08	71.22	76.68	36.41	3.72	4.01
Other Long-Term Liabilities	160.22	145.54	112.64	135.75	67.82	1.34
Total Long-Term Liabilities	228.3	216.76	189.31	172.16	71.54	5.34
Total Liabilities	333.18	335.78	307.63	292.84	175.03	13.24
Total Debt	68.08	71.22	76.68	36.41	3.72	6.09
Debt Growth	-11.89%	-7.11%	110.57%	880.16%	-38.95%	76.76%
Retained Earnings	239.18	279.79	426.19	267.67	114.2	-4.72
Comprehensive Income	-1.82	-1.72	-1.39	0.28	0	0
Shareholders' Equity	1,130	1,152	1,233	1,026	830.51	10.25
Net Cash / Debt	654.94	714.36	834.81	711.56	590.4	1.47
Net Cash / Debt Growth	-12.00%	-14.43%	17.32%	20.52%	40118.05%	-79.03%
Net Cash Per Share	2.24	2.47	2.65	2.24	2.24	0.01
Working Capital	709.07	752.97	907.17	809.12	709.84	4.75
Book Value Per Share	3.86	3.98	4.33	3.72	5.22	0.07

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).